Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runcaciguat in chronic kidney disease with cardiovascular comorbidity
2019-003297-53Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), Arterionephrosclerosis (ANS) and 1 more comparing Runcaciguat titrated once daily with Placebo once daily (2 arms). Started Feb 2020; status: completed.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)Arterionephrosclerosis (ANS)cardiac morbidity
Beyond the preview
Go deeper on 2019-003297-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003297-53.